E 10215

Drug Profile

E 10215

Alternative Names: E-10215

Latest Information Update: 05 Apr 2016

Price : $50

At a glance

  • Originator Elorac
  • Class Antiacnes; Antibacterials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acne

Most Recent Events

  • 05 Apr 2016 Phase-I development is ongoing in USA
  • 14 Jan 2015 Phase-I clinical trials in Acne in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top